INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

KNSAKiniksa Pharmaceuticals International, plc

CIK 0001730430

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 16
Max Insider Score19
Connections6with evidence

KNSA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$68K
722 sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Malkani Dhiraj HCHIEF STRATEGY OFFICER · Jul 6, 2026
  • ← Insider ofevidence
    Moat RossCHIEF OPERATING OFFICER · Apr 8, 2026
  • ← Insider ofevidence
    Paolini John F.CHIEF MEDICAL OFFICER · Apr 8, 2026
8
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL
$171K
1,760 sh
Oct 30, 2026
Nov 3, 2026
traded Oct 30, 2026
+4d
SEC FORM 4

Evidence

15
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$252K
2,575 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

7
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$170K
9,412 sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

8
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$610K
6,681 sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

12
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$822K
8,932 sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

19
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$1.08M
11.6K sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
16.1K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$143K
6,263 sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

10
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$268K
12.3K sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
6,263 sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

4
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
12.3K sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

4
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
9,412 sh
Nov 2, 2026Nov 3, 2026
traded Nov 2, 2026
+1dSEC FORM 4

Evidence

7
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
10.9K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
16.1K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
1,658 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
3,760 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
21.1K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

10
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$173K
16.1K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

10
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$234K
21.1K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$45K
3,760 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$22K
1,658 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

9
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$286K
16.1K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

2
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$197K
10.9K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

18
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$3.48M
37.8K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

18
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$1.40M
15.1K sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

15
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$792K
8,430 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

15
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$596K
6,282 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

15
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$353K
3,672 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

15
MH
Malkani Dhiraj HCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Grant or award
A—
1,307 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

15
MH
Malkani Dhiraj HCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Grant or award
A—
1,245 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

15
MH
Malkani Dhiraj HCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Grant or award
A—
2,188 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

15
MH
Malkani Dhiraj HCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Grant or award
A—
2,119 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

15
MH
Malkani Dhiraj HCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Grant or award
A—
14.0K sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

15
MH
Malkani Dhiraj HCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Grant or award
A—
82.6K sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

8
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$80K
1,703 sh
Apr 9, 2026Apr 13, 2026
traded Apr 9, 2026
+4dSEC FORM 4

Evidence

12
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Tax withholding
F$64K
1,303 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

9
TE
Tessari EbenCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise
M—
2,726 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

5
TE
Tessari EbenCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Tax withholding
F$41K
846 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

5
TE
Tessari EbenCHIEF STRATEGY OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise
M—
2,726 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

12
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$115K
2,367 sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

3
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
2,477 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Tax withholding · 10b5-1 plan
F$38K
774 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
MR
Moat RossCHIEF OPERATING OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
2,477 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

9
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise
M—
2,694 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

5
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise
M—
2,694 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

9
PF
Paolini John F.CHIEF MEDICAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise
M—
2,497 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

12
PF
Paolini John F.CHIEF MEDICAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Tax withholding
F$59K
1,208 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

9
PF
Paolini John F.CHIEF MEDICAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise
M—
2,497 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

15
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$382K
8,731 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

0
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
8,374 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

0
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
2,471 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

6
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$109K
8,374 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

0
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$42K
2,471 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

15
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$391K
9,114 sh
Feb 9, 2026Feb 11, 2026
traded Feb 9, 2026
+2dSEC FORM 4

Evidence

15
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Open-market sale · 10b5-1 plan
SELL$503K
12.0K sh
Jan 8, 2026Jan 9, 2026
traded Jan 8, 2026
+1dSEC FORM 4

Evidence

2
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$113K
10.5K sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

6
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$193K
16.2K sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

10
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M$179K
16.2K sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

7
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
10.5K sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Tessari EbenCHIEF OPERATING OFFICER · Nov 19, 2025
  • ← Insider ofevidence
    Ragosa MarkCHIEF FINANCIAL OFFICER · Nov 14, 2025